Burlington, Ontario--(Newsfile Corp. - May 22, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") trading on…
PRINCETON, NJ / ACCESSWIRE / May 22, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage…
Moderna to host an investor event via webcast on Monday, June 3 at 6:15 PM CDTCAMBRIDGE, MA / ACCESSWIRE /…
The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher…
NV-387, A Broad-Spectrum Antiviral with Strong Activity Against RSV, Influenza A, Coronaviruses, Others SHELTON, CT / ACCESSWIRE / May 20,…
This Collaboration is Focused on Advancing the Design of the MACH-1 System, Preparing It for Phase 1 Clinical TrialsSEATTLE, WA…
NV-387 Advancing to Phase II Clinical Trial for the Treatment of RSV Infection SHELTON, CT / ACCESSWIRE / May 15,…
Published Phase 1 data of SON-1010 in Frontiers in Immunology demonstrating the safety and tolerability of the F H AB-derived…
Complete Survival of Animals Lethally Infected into Lungs with RSV Achieved Upon NV-387 Oral Treatment SHELTON, CT / ACCESSWIRE /…
Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase…